Cancer play Syndax pulls IPO

Syndax Pharmaceuticals Inc. (Waltham, Mass.) withdrew its IPO on NASDAQ. The company did not give a reason in a regulatory filing, and declined comment to BioCentury. Planned underwriters were Deutsche Bank; Jefferies; JMP Securities; and Wedbush PacGrow.

Syndax said in June it planned to sell 4.3 million shares at $13-$15. At $14, it would have raised $60.2 million and been valued at $170.5 million. The company amended its IPO in November, removing the proposed number of shares and price range. ...